OBJECTIVES:CD4+ T cells sustain the chronic synovial inflammatory response in rheumatoid arthritis (RA). SB-210396/CE 9.1 is an anti-CD4 monoclonal antibody that has documented efficacy in RA when given intravenously. This study aimed to establish the safety and efficacy of the intra-articular administration of SB-210396/CE 9.1 compared with placebo, examining its mode of action using a combined imaging approach of arthroscopy, magnetic resonance imaging (MRI), and histology. METHODS:Thirteen RA patients with active, resistant knee synovitis, were randomised to intra-articular injection of placebo (n=3), 0.4 mg (n=3) or 40 mg (n=7) of anti-CD4 after sequential dynamic gadolinium enhanced MRI, followed by same day arthroscopy and synovial membrane biopsy. Imaging and arthroscopic synovial membrane sampling were repeated at six weeks. This study used a unique region of interest (ROI) analysis mapping the MRI area analysed to the specific biopsy site identified arthroscopically, thus providing data for all three modalities at the same synovial membrane site. RESULTS:12 patients completed the study (one placebo treated patient refused further MRI). Arthroscopic improvement was observed in 0 of 2 placebo patients but in 10 of 10 patients receiving active drug (>20% in 6 of 10). Improvement in MRI was consistently observed in all patients of the 40 mg group but not in the other two groups. A reduction in SM CD4+ score was noted in the 40 mg group and in the 0.4 mg group. Strong correlations both before and after treatment, were identified between the three imaging modalities. Intra-articular delivery of SB-210396/CE 9.1 was well tolerated. CONCLUSIONS:SB-210396/CE 9.1 is safe when administered by intra-articular injection. A trend toward efficacy was found by coordinated MRI, arthroscopic, and histological imaging, not seen in the placebo group. The value of ROI analysis was demonstrated.
RCT Entities:
OBJECTIVES:CD4+ T cells sustain the chronic synovial inflammatory response in rheumatoid arthritis (RA). SB-210396/CE 9.1 is an anti-CD4 monoclonal antibody that has documented efficacy in RA when given intravenously. This study aimed to establish the safety and efficacy of the intra-articular administration of SB-210396/CE 9.1 compared with placebo, examining its mode of action using a combined imaging approach of arthroscopy, magnetic resonance imaging (MRI), and histology. METHODS: Thirteen RApatients with active, resistant knee synovitis, were randomised to intra-articular injection of placebo (n=3), 0.4 mg (n=3) or 40 mg (n=7) of anti-CD4 after sequential dynamic gadolinium enhanced MRI, followed by same day arthroscopy and synovial membrane biopsy. Imaging and arthroscopic synovial membrane sampling were repeated at six weeks. This study used a unique region of interest (ROI) analysis mapping the MRI area analysed to the specific biopsy site identified arthroscopically, thus providing data for all three modalities at the same synovial membrane site. RESULTS: 12 patients completed the study (one placebo treated patient refused further MRI). Arthroscopic improvement was observed in 0 of 2 placebo patients but in 10 of 10 patients receiving active drug (>20% in 6 of 10). Improvement in MRI was consistently observed in all patients of the 40 mg group but not in the other two groups. A reduction in SM CD4+ score was noted in the 40 mg group and in the 0.4 mg group. Strong correlations both before and after treatment, were identified between the three imaging modalities. Intra-articular delivery of SB-210396/CE 9.1 was well tolerated. CONCLUSIONS:SB-210396/CE 9.1 is safe when administered by intra-articular injection. A trend toward efficacy was found by coordinated MRI, arthroscopic, and histological imaging, not seen in the placebo group. The value of ROI analysis was demonstrated.
Authors: R A Robb; D P Hanson; R A Karwoski; A G Larson; E L Workman; M C Stacy Journal: Comput Med Imaging Graph Date: 1989 Nov-Dec Impact factor: 4.790
Authors: C Herzog; C Walker; W Müller; P Rieber; C Reiter; G Riethmüller; P Wassmer; H Stockinger; O Madic; W J Pichler Journal: J Autoimmun Date: 1989-10 Impact factor: 7.094
Authors: G Gilkeson; R Polisson; H Sinclair; J Vogler; J Rice; D Caldwell; C Spritzer; S Martinez Journal: J Rheumatol Date: 1988-09 Impact factor: 4.666
Authors: D E Trentham; J A Belli; R J Anderson; J A Buckley; E J Goetzl; J R David; K F Austen Journal: N Engl J Med Date: 1981-10-22 Impact factor: 91.245
Authors: Mary Canavan; Alice M Walsh; Vipul Bhargava; Sarah M Wade; Trudy McGarry; Viviana Marzaioli; Barry Moran; Monika Biniecka; Hannah Convery; Siobhan Wade; Carl Orr; Ronan Mullan; Jean M Fletcher; Sunil Nagpal; Douglas J Veale; Ursula Fearon Journal: JCI Insight Date: 2018-12-06
Authors: Richard J Hodgson; Theresa Barnes; Sylvia Connolly; Brian Eyes; Robert S D Campbell; Robert Moots Journal: Skeletal Radiol Date: 2007-12-05 Impact factor: 2.199
Authors: Márcio Navalho; Catarina Resende; Ana Maria Rodrigues; Augusto Gaspar; João Eurico Fonseca; Helena Canhão; Jorge Campos Journal: Skeletal Radiol Date: 2011-02-12 Impact factor: 2.199
Authors: Erik af Klint; Anca I Catrina; Peter Matt; Petra Neregråd; Jon Lampa; Ann-Kristin Ulfgren; Lars Klareskog; Staffan Lindblad Journal: Arthritis Res Ther Date: 2009-06-02 Impact factor: 5.156